Anti-lipoapoptotic effect of Artemisia capillaris extract on free fatty acids-induced HepG2 cells

BMC Complementary and Alternative Medicine

Hyeung-Jin Jang²  Jang-Hoon Lee²  Youngchul Kim²  Hong-Jung Woo²  Yun-Cheol Na¹  Yoomi Kim¹  Ki-Suk Kim²  Min-Hee Shin²  Eungyeong Jang² 

[1] Integrated Metabolomics Research Group, Seoul Center, Korea Basic Science Institute, 126-16 Anam-Dong, Seungbuk-Ku, Seoul 136-713, Republic of Korea;College of Korean Medicine, Institute of Korean Medicine, Kyung Hee University, Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Republic of Korea

关键词: p53 up-regulated mediator of apoptosis (PUMA);    c-Jun NH₂-terminal kinase (JNK);    Lipoapoptosis;    Non-alcoholic steatohepatitis (NASH);    HepG2;    Artemisia capillaris (AC);   

Others  :  1087287
DOI  :  10.1186/1472-6882-14-253

 received in 2014-03-05, accepted in 2014-07-10,  发布年份 2014

【 摘 要 】

Background

Artemisia capillaris (AC) has been recognized as one of the promising candidates for hepatoprotective, hypoglycemic, hypolipidemic, antiobesitic and anti-inflammatory therapeutic effectiveness. This study evaluated the inherent mechanism and anti-apoptotic activity of 30% ethanol extract of AC (AC extract) 100 μg/ml on free fatty acids (FFAs)-induced HepG2 cellular steatosis and lipoapoptosis.

Methods

Hepatic steatosis was induced by culturing HepG2 cells with a FFAs mixture (oleic and palmitic acid at the proportion of 2:1) for 24 h, thus ultimately giving rise to lipoapoptosis. Cell viability and lipid accumulation were detected by MTT assay and Oil Red O staining method respectively and Caspase-3, −9, Bax, Bcl-2, p-JNK and PUMA were measured for lipoapoptosis after 24 hours.

Results

AC extract significantly improved the FFAs-induced steatosis without cytotoxicity and Caspase-3, −9, Bax and Bcl-2 were modulated profitably to HepG2 cells after AC treatment. In addition, AC extract inhibited the activation of c-Jun NH₂ terminal kinase (JNK) and PUMA, which mechanism is related to non-alcoholic steatohepatitis (NASH).

Conclusions

Combined together, AC extract exerted an obvious hypolipidemic and anti-apoptotic effect, indicating that AC extract might have potential therapeutic herb against NASH.

【 授权许可】

   
2014 Jang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Snel M, Jonker JT, Schoones J, Lamb H, Roos A, Pijl H, Smit JWA, Meinders AE, Jazet IM: Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol 2012, 2012:18.
• [2]Targher G, Byrne CD: Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013, 98(2):483-495.
• [3]Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
• [4]Lavine JE, Schwimmer JB: Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004, 8(3):549-558. viii-ix
• [5]Reddy JK, Rao MS: Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006, 290(5):G852-858.
• [6]Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl 1):S99-s112.
• [7]Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA: Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141(4):1249-1253.
• [8]Hashimoto E, Tokushige K: Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011, 46(Suppl 1):63-69.
• [9]Durazzo M, Belci P, Collo A, Grisoglio E, Bo S: Focus on therapeutic strategies of nonalcoholic fatty liver disease. Int J Hepatol 2012, 2012:9.
• [10]Leamy AK, Egnatchik RA, Young JD: Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 2013, 52(1):165-174.
• [11]Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ: Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 2007, 56(8):1124-1131.
• [12]Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125(2):437-443.
• [13]Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE: In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44(1):27-33.
• [14]Malhi H, Bronk SF, Werneburg NW, Gores GJ: Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006, 281(17):12093-12101.
• [15]Cha JD, Jeong MR, Jeong SI, Moon SE, Kim JY, Kil BS, Song YH: Chemical composition and antimicrobial activity of the essential oils of Artemisia scoparia and A. capillaris. Planta Med 2005, 71(2):186-190.
• [16]Son CG, Choi WJ, Shin JW, Han SH, Cho JH, Song KC, Cho CK: Effects of gamichunggantang on hyperlipidemia. Acta Pharmacol Sin 2003, 24(2):133-139.
• [17]Pan J, Liu G, Liu H, Qiu Z, Chen L: Effects of artemisia capillaris on blood glucose and lipid in mice. Zhong Yao Cai 1998, 21(8):408-411.
• [18]J-y Y, J-h L: Effects of Saenggantanggami-bang on Nonalcoholic Fatty Liver Disease Model Induced by Fatty Acids. Korean J Orientint Med 2010, 31(2):331-345.
• [19]Hong JH, Hwang EY, Kim HJ, Jeong YJ, Lee IS: Artemisia capillaris inhibits lipid accumulation in 3 T3-L1 adipocytes and obesity in C57BL/6 J mice fed a high fat diet. J Med Food 2009, 12(4):736-745.
• [20]Wang JH, Choi MK, Shin JW, Hwang SY, Son CG: Antifibrotic effects of Artemisia capillaris and Artemisia iwayomogi in a carbon tetrachloride-induced chronic hepatic fibrosis animal model. J Ethnopharmacol 2012, 140(1):179-185.
• [21]Hong J-H, Lee J-W, Park J-H, Lee I-S: Antioxidative and cytoprotective effects of Artemisia capillaris fractions. BioFactors 2007, 31(1):43-53.
• [22]Jang SI, Kim YJ, Lee WY, Kwak KC, Baek SH, Kwak GB, Yun YG, Kwon TO, Chung HT, Chai KY: Scoparone from Artemisia capillaris inhibits the release of inflammatory mediators in RAW 264.7 cells upon stimulation cells by interferon-gamma Plus LPS. Arch Pharm Res 2005, 28(2):203-208.
• [23]Lee SG, Jeong HJ, Lee EJ, Kim J, Choi SW: Antioxidant and Anti-inflammatory Activities of Ethanol Extracts from Medicinal Herb Mixtures. Korean J Food SCI Technol 2011, 43(2):200-205.
• [24]Liu JF, Ma Y, Wang Y, Du ZY, Shen JK, Peng HL: Reduction of lipid accumulation in HepG2 cells by luteolin is associated with activation of AMPK and mitigation of oxidative stress. Phytother Res 2011, 25(4):588-596.
• [25]Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolotti M, Banni S, Lonardo A, Carulli N, Loria P: Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 2009, 24(5):830-840.
• [26]Cazanave SC, Elmi NA, Akazawa Y, Bronk SF, Mott JL, Gores GJ: CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 2010, 299(1):G236-243.
• [27]Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ: JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 2009, 284(39):26591-26602.
• [28]Tolman KG, Dalpiaz AS: Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag 2007, 3(6):1153-1163.
• [29]Taylor RC, Cullen SP, Martin SJ: Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008, 9(3):231-241.
• [30]Nakano K, Vousden KH: PUMA, a Novel Proapoptotic Gene, Is Induced by p53. Mol Cell 2001, 7(3):683-694.
• [31]Malhi H, Gores GJ: Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28(4):360-369.
• [32]Unger RH, Orci L: Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002, 1585(2–3):202-212.
• [33]Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ: A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46(4):1081-1090.
• [34]Xu L, Hui AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ: Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005, 54(1):142-151.
• [35]Chavez-Tapia NC, Rosso N, Tiribelli C: In vitro models for the study of non-alcoholic fatty liver disease. Curr Med Chem 2011, 18(7):1079-1084.
• [36]De Gottardi A, Vinciguerra M, Sgroi A, Moukil M, Ravier-Dall'Antonia F, Pazienza V, Pugnale P, Foti M, Hadengue A: Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab Invest 2007, 87(8):792-806.
• [37]Yamashita R, Saito T, Satoh S, Aoki K, Kaburagi Y, Sekihara H: Effects of dehydroepiandrosterone on gluconeogenic enzymes and glucose uptake in human hepatoma cell line, HepG2. Endocr J 2005, 52(6):727-733.
• [38]Yao HR, Liu J, Plumeri D, Cao YB, He T, Lin L, Li Y, Jiang YY, Li J, Shang J: Lipotoxicity in HepG2 cells triggered by free fatty acids. Am J Transl Res 2011, 3(3):284-291.
• [39]Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J: Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106(6):635-643.
• [40]Kakisaka K, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, Werneburg NW, Mott JL, Gores GJ: Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 2012, 302(1):G77-84.
• [41]Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, Sanyal AJ: Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008, 134(2):568-576.
• [42]Singh R, Wang Y, Xiang Y, Tanaka KE, Gaarde WA, Czaja MJ: Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 2009, 49(1):87-96.
• [43]Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, Oren M: Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. Embo j 1997, 16(6):1381-1390.
• [44]Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B: PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001, 7(3):673-682.
• [45]Armstrong MJ, Houlihan DD, Rowe IA: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 363(12):1185. author reply 1186
• [46]Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH: Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009, 29(2):172-182.